These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27987630)

  • 1. Order of Presentation of Dimensions Does Not Systematically Bias Utility Weights from a Discrete Choice Experiment.
    Norman R; Kemmler G; Viney R; Pickard AS; Gamper E; Holzner B; Nerich V; King M
    Value Health; 2016 Dec; 19(8):1033-1038. PubMed ID: 27987630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30.
    King MT; Viney R; Simon Pickard A; Rowen D; Aaronson NK; Brazier JE; Cella D; Costa DSJ; Fayers PM; Kemmler G; McTaggart-Cowen H; Mercieca-Bebber R; Peacock S; Street DJ; Young TA; Norman R;
    Pharmacoeconomics; 2018 Feb; 36(2):225-238. PubMed ID: 29270835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Japanese value set for the EORTC QLU-C10D: A multi-attribute utility instrument based on the EORTC QLQ-C30 cancer-specific quality-of-life questionnaire.
    Shiroiwa T; King MT; Norman R; Müller F; Campbell R; Kemmler G; Murata T; Shimozuma K; Fukuda T
    Qual Life Res; 2024 Jul; 33(7):1865-1879. PubMed ID: 38724771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. U.K. utility weights for the EORTC QLU-C10D.
    Norman R; Mercieca-Bebber R; Rowen D; Brazier JE; Cella D; Pickard AS; Street DJ; Viney R; Revicki D; King MT;
    Health Econ; 2019 Dec; 28(12):1385-1401. PubMed ID: 31482619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. German value sets for the EORTC QLU-C10D, a cancer-specific utility instrument based on the EORTC QLQ-C30.
    Kemmler G; Gamper E; Nerich V; Norman R; Viney R; Holzner B; King M;
    Qual Life Res; 2019 Dec; 28(12):3197-3211. PubMed ID: 31485913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. United States Utility Algorithm for the EORTC QLU-C10D, a Multiattribute Utility Instrument Based on a Cancer-Specific Quality-of-Life Instrument.
    Revicki DA; King MT; Viney R; Pickard AS; Mercieca-Bebber R; Shaw JW; Müller F; Norman R
    Med Decis Making; 2021 May; 41(4):485-501. PubMed ID: 33813946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format.
    Norman R; Viney R; Aaronson NK; Brazier JE; Cella D; Costa DS; Fayers PM; Kemmler G; Peacock S; Pickard AS; Rowen D; Street DJ; Velikova G; Young TA; King MT
    Qual Life Res; 2016 Mar; 25(3):637-49. PubMed ID: 26342928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dutch utility weights for the EORTC cancer-specific utility instrument: the Dutch EORTC QLU-C10D.
    Jansen F; Verdonck-de Leeuw IM; Gamper E; Norman R; Holzner B; King M; Kemmler G;
    Qual Life Res; 2021 Jul; 30(7):2009-2019. PubMed ID: 33512653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Test-Retest Reliability of Discrete Choice Experiment for Valuations of QLU-C10D Health States.
    Gamper EM; Holzner B; King MT; Norman R; Viney R; Nerich V; Kemmler G
    Value Health; 2018 Aug; 21(8):958-966. PubMed ID: 30098674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The EORTC QLU-C10D discrete choice experiment for cancer patients: a first step towards patient utility weights.
    Gamper EM; King MT; Norman R; Loth FLC; Holzner B; Kemmler G;
    J Patient Rep Outcomes; 2022 May; 6(1):42. PubMed ID: 35507194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The EORTC QLU-C10D: the Hong Kong valuation study.
    Xu RH; Wong EL; Luo N; Norman R; Lehmann J; Holzner B; King MT; Kemmler G;
    Eur J Health Econ; 2024 Jul; 25(5):889-901. PubMed ID: 37768519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. French Value-Set of the QLU-C10D, a Cancer-Specific Utility Measure Derived from the QLQ-C30.
    Nerich V; Gamper EM; Norman R; King M; Holzner B; Viney R; Kemmler G
    Appl Health Econ Health Policy; 2021 Mar; 19(2):191-202. PubMed ID: 32537694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EORTC QLU-C10D value sets for Austria, Italy, and Poland.
    Gamper EM; King MT; Norman R; Efficace F; Cottone F; Holzner B; Kemmler G;
    Qual Life Res; 2020 Sep; 29(9):2485-2495. PubMed ID: 32458409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The European Organisation for Research and Treatment of Cancer Quality of Life Utility-Core 10 Dimensions: Development and Investigation of General Population Utility Norms for Canada, France, Germany, Italy, Poland, and the United Kingdom.
    Pilz MJ; Nolte S; Liegl G; King M; Norman R; McTaggart-Cowan H; Bottomley A; Rose M; Kemmler G; Holzner B; Gamper EM;
    Value Health; 2023 May; 26(5):760-767. PubMed ID: 36572102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Danish value sets for the EORTC QLU-C10D utility instrument.
    Lehmann J; Rojas-Concha L; Petersen MA; Holzner B; Norman R; King MT; Kemmler G;
    Qual Life Res; 2024 Mar; 33(3):831-841. PubMed ID: 38183563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The EORTC QLU-C10D: The Canadian Valuation Study and Algorithm to Derive Cancer-Specific Utilities From the EORTC QLQ-C30.
    McTaggart-Cowan H; King MT; Norman R; Costa DSJ; Pickard AS; Regier DA; Viney R; Peacock SJ
    MDM Policy Pract; 2019; 4(1):2381468319842532. PubMed ID: 31245606
    [No Abstract]   [Full Text] [Related]  

  • 17. A pilot discrete choice experiment to explore preferences for EQ-5D-5L health states.
    Norman R; Cronin P; Viney R
    Appl Health Econ Health Policy; 2013 Jun; 11(3):287-98. PubMed ID: 23649892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How Should Discrete Choice Experiments with Duration Choice Sets Be Presented for the Valuation of Health States?
    Mulhern B; Norman R; Shah K; Bansback N; Longworth L; Viney R
    Med Decis Making; 2018 Apr; 38(3):306-318. PubMed ID: 29084472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valuing SF-6D Health States Using a Discrete Choice Experiment.
    Norman R; Viney R; Brazier J; Burgess L; Cronin P; King M; Ratcliffe J; Street D
    Med Decis Making; 2014 Aug; 34(6):773-86. PubMed ID: 24025661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health state utility differed systematically in breast cancer patients between the EORTC QLU-C10D and the PROMIS Preference Score.
    Klapproth CP; Fischer F; Rose M; Karsten MM
    J Clin Epidemiol; 2022 Dec; 152():101-109. PubMed ID: 36162712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.